Compare iShares MSCI Indonesia ETF (EIDO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Indonesia ETF trades at $11.98 (market cap $409.22M), while State Street SPDR S&P Biotech ETF trades at $153.7 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 24.7× iShares MSCI Indonesia ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EIDO | XBI | |
|---|---|---|
Market Cap | $409.22M | $10.11B |
Volume | 879,527 | 12,903,266 |
52-Week High | $19.22 | $169.55 |
52-Week Low | $10.80 | $104.99 |
Typical Hold Time | 76 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.89, up 0.25% with bearish technical signals from moving averages. The ETF faces headwinds from foreign capital outflows in Asian equities and limited upside from its heavy financials weighting. Recent news highlights Indonesia's underperformance despite commodity gains, with trading volume declining 21% below average.
Outlook remains cautious given technical downtrend and sector concentration risks. The ETF's bargain 8.7x P/E offers value but weak price action and low EPS growth constrain momentum. Key risks include regional capital rotation and dependence on financial sector performance.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
